CCRA Introduction to Certified Clinical Research Associate 4 — Questions and Answers
Question 1: Which document defines the objectives, design, methodology, statistical considerations, and organization of a clinical trial?
- The clinical trial protocol (Correct answer)
- The Investigator's Brochure
- The Case Report Form
- The Clinical Study Report
Correct answer: The clinical trial protocol
The clinical trial protocol is the master document that provides the scientific rationale, objectives, design, methodology, and statistical plan for the study.
Question 2: Under GCP, which of the following is the investigator's responsibility with respect to the investigational product (IP)?
- Maintaining accountability records for receipt, use, and disposition of the IP (Correct answer)
- Manufacturing the IP according to GMP standards
- Approving the IP formulation before shipment
- Setting the price of the IP for commercial distribution
Correct answer: Maintaining accountability records for receipt, use, and disposition of the IP
Investigators must maintain accurate accountability records for all investigational product received, dispensed, used, and returned or destroyed.
Question 3: What is the purpose of the Investigator's Brochure (IB)?
- To provide the clinical and non-clinical data on the investigational product relevant to its study in humans (Correct answer)
- To serve as the official FDA approval document for the drug
- To document subject-reported outcomes during the trial
- To record investigator qualifications and training history
Correct answer: To provide the clinical and non-clinical data on the investigational product relevant to its study in humans
The IB compiles all relevant preclinical and clinical data about the investigational product to guide safe and appropriate conduct of the trial.
Question 4: Which of the following best describes a 'serious adverse event' (SAE) per ICH E2A?
- Any adverse event that results in death, is life-threatening, requires hospitalization, or causes persistent disability (Correct answer)
- Any adverse event that causes mild discomfort or requires dose reduction
- Any expected side effect listed in the Investigator's Brochure
- Any laboratory abnormality regardless of clinical significance
Correct answer: Any adverse event that results in death, is life-threatening, requires hospitalization, or causes persistent disability
An SAE is defined by ICH E2A as any adverse event that results in death, is life-threatening, requires inpatient hospitalization, causes persistent significant disability, or is a congenital anomaly.
Question 5: How long after its occurrence must a sponsor report a suspected unexpected serious adverse reaction (SUSAR) to the FDA for fatal or life-threatening events?
- Within 7 calendar days (Correct answer)
- Within 15 calendar days
- Within 30 calendar days
- Within 24 hours
Correct answer: Within 7 calendar days
Fatal or life-threatening SUSARs must be reported to the FDA within 7 calendar days of the sponsor's first receipt of information, per 21 CFR 312.32.
Question 6: In the context of a clinical trial, what does 'randomization' achieve?
- It reduces selection bias by ensuring subjects are assigned to treatment groups by chance (Correct answer)
- It ensures all subjects receive the same treatment
- It eliminates the need for a control group
- It determines which sites are selected to participate in the trial
Correct answer: It reduces selection bias by ensuring subjects are assigned to treatment groups by chance
Randomization minimizes selection bias and helps ensure that treatment groups are comparable by assigning subjects to groups by chance rather than choice.
Question 7: What is the primary regulatory framework governing the protection of human research subjects in federally funded research in the United States?
- The Common Rule (45 CFR Part 46) (Correct answer)
- The Food, Drug, and Cosmetic Act (FD&C Act)
- The Health Insurance Portability and Accountability Act (HIPAA)
- The International Conference on Harmonisation (ICH) E6
Correct answer: The Common Rule (45 CFR Part 46)
The Common Rule (45 CFR Part 46) is the primary federal regulation for protecting human subjects in research conducted or supported by federal agencies.
CCRA Introduction to Certified Clinical Research Associate 4
Which document defines the objectives, design, methodology, statistical considerations, and organization of a clinical trial?